(0.82%) 5 087.75 points
(0.61%) 38 302 points
(0.98%) 17 610 points
(0.58%) $79.46
(2.43%) $1.979
(0.03%) $2 311.80
(-0.91%) $26.51
(0.84%) $962.90
(0.14%) $0.934
(0.30%) $11.06
(0.05%) $0.799
(-1.35%) $92.01
5.56% HKD 5.70
Live Chart Being Loaded With Signals
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China...
Stats | |
---|---|
Dzisiejszy wolumen | 2.16M |
Średni wolumen | 5.11M |
Kapitalizacja rynkowa | 14.88B |
EPS | HKD0 ( 2024-03-28 ) |
Następna data zysków | ( HKD0 ) 2024-06-14 |
Last Dividend | HKD0.176 ( 2023-06-19 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 19.66 |
ATR14 | HKD0.00500 (0.09%) |
Wolumen Korelacja
Simcere Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Simcere Pharmaceutical Korelacja - Waluta/Towar
Simcere Pharmaceutical Finanse
Annual | 2023 |
Przychody: | HKD6.61B |
Zysk brutto: | HKD4.98B (75.43 %) |
EPS: | HKD0.270 |
FY | 2023 |
Przychody: | HKD6.61B |
Zysk brutto: | HKD4.98B (75.43 %) |
EPS: | HKD0.270 |
FY | 2023 |
Przychody: | HKD0 |
Zysk brutto: | HKD0 (0.00 %) |
EPS: | HKD0 |
FY | 2022 |
Przychody: | HKD6.32B |
Zysk brutto: | HKD5.00B (79.08 %) |
EPS: | HKD0.400 |
Financial Reports:
No articles found.
Simcere Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.176 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.180 | 2021-06-29 |
Last Dividend | HKD0.176 | 2023-06-19 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.532 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.45 | -- |
Div. Sustainability Score | 8.58 | |
Div.Growth Potential Score | 4.22 | |
Div. Directional Score | 6.40 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9959.HK | No Dividend Player | 2023-06-16 | Insufficient data to determine frequency | 0 | 0.00% | |
2182.HK | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
1184.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
0257.HK | Ex Dividend Junior | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
3898.HK | Ex Dividend Knight | 2023-06-29 | Annually | 0 | 0.00% | |
1760.HK | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
0806.HK | Ex Dividend Junior | 2023-05-03 | Annually | 0 | 0.00% | |
2342.HK | Ex Dividend Knight | 2023-09-07 | Annually | 0 | 0.00% | |
1314.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
0375.HK | Ex Dividend Knight | 2023-09-27 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.108 | 1.500 | 7.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0659 | 1.200 | 7.80 | 9.37 | [0 - 0.3] |
returnOnEquityTTM | 0.0878 | 1.500 | -0.135 | -0.203 | [0.1 - 1] |
payoutRatioTTM | 0.587 | -1.000 | 4.13 | -4.13 | [0 - 1] |
currentRatioTTM | 2.10 | 0.800 | 4.50 | 3.60 | [1 - 3] |
quickRatioTTM | 1.736 | 0.800 | 4.49 | 3.59 | [0.8 - 2.5] |
cashRatioTTM | 0.747 | 1.500 | 6.96 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.132 | -1.500 | 7.81 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0581 | 2.00 | 9.98 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.128 | 2.00 | -0.0639 | -0.128 | [0 - 20] |
debtEquityRatioTTM | 0.198 | -1.500 | 9.21 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.754 | 1.000 | 0.762 | 0.762 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.108 | 1.000 | 9.85 | 9.85 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.106 | 1.000 | -0.524 | -0.524 | [0.2 - 2] |
assetTurnoverTTM | 0.609 | 0.800 | 9.27 | 7.42 | [0.5 - 2] |
Total Score | 8.58 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.53 | 1.000 | 8.23 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0878 | 2.50 | -0.0869 | -0.203 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.128 | 2.00 | -0.0426 | -0.128 | [0 - 30] |
dividendYielPercentageTTM | 3.45 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0581 | 2.00 | 9.98 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.587 | 1.500 | 4.13 | -4.13 | [0 - 1] |
pegRatioTTM | 0.523 | 1.500 | 9.85 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0229 | 1.000 | -1.929 | 0 | [0.1 - 0.5] |
Total Score | 4.22 |
Simcere Pharmaceutical
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej